ASCO 2023
279 abstracts
Abstract
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.Org: Memorial Sloan Kettering Cancer Center, Erasmus MC Cancer Institute, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Pitié Salpêtrière Hospital, Duke University Medical Center,
Abstract
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).Org: Memorial Sloan Kettering Cancer Center, Alliance Statistics and Data Center, Mayo Clinic, Department of Radiology, Department of Colorectal Oncology,
Abstract
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).Org: Medical Oncology, Yale School of Medicine, Yale Cancer Center, Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).Org: City of Hope National Medical Center, Emory University School of Medicine, Weill Cornell Medicine, Research Institute of McGill University Health Centre, Princess Margaret - University Health Network,
Abstract
Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.Org: Kent Oncology Centre, Istituto Europeo Oncologico, Hôpital Européen Georges Pompidou, Medica Scientia Innovation Research (MEDSIR), Pangaea Oncology,
Abstract
Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.Org: Gustave Roussy Cancer Center, CARIO - HPCA, Department of Genetics, Claudius Regaud Institute, Eugène Marquis Comprehensive Cancer Center,
Abstract
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).Org: Dana-Farber Cancer Institute, Medical Faculty Mannheim, Pangaea Oncology, Queen Mary University of London, Centre Léon Bérard,
Abstract
A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).Org: Sarah Cannon Research Institute/Tennessee Oncology, Daiichi Sankyo Inc., Rutgers Cancer Institue of New Jersey, Highlands Oncology, Washington University School of Medicine,
Abstract
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies.Org: Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School,
Abstract
An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.Org: University Hospital Leuven, International Breast Cancer Centre (IBCC), Quironsalud Group, Aichi Cancer Center Hospital, Vall d’Hebron University Hospital/VHIO,
Abstract
Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.Org: Westwood, Kansas City, Department of Biostatistics & Data Science, Central Care Cancer Ctr, The University of Kansas Cancer Center,
Abstract
CANKADO PRO-React eHealth support in patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy and the affect on time to deterioration of quality of life: Primary outcome analysis of the multicenter randomized PreCycle trial.Org: Breast Center, LMU University Hospital, Comprehensive Cancer Center Erlangen-EMN, Joint practice Wolfratshausen, Medical University of Brandenburg,
Abstract
Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.Org: University of Oxford, Centre for Public Health, Karolinska Institutet, Fred Hutchinson Cancer Research Center, Peter MacCallum Cancer Centre, Melbourne, Australia,
Abstract
Association of tumor-infiltrating lymphocytes (TILs) with clinicopathologic characteristics and prognosis in young women with HR+/HER2- breast cancer (BC).Org: Dana-Farber Cancer Institute, Weill Cornell Medicine, Stanford Comprehensive Cancer Institute, University of Colorado Cancer Center, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).Org: Tennessee Oncology, PLLC, University General Hospital of Heraklion, Hospital de Cancer de Londrina, Baskent University Faculty of Medicine, Mater Adult Hospital Brisbane,
Abstract
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.Org: Royal Cancer Hospital, Heidelberg University, Department of Oncology, National Taiwan University Hospital, Asan Medical Center, Service de Oncología Médica,
Abstract
Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial.Org: University of Chicago, European Institute of Oncology, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Peter MacCallum Cancer Centre, Melbourne, Australia, International Breast Cancer Study Group,
Abstract
Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.Org: University of Kansas Cancer Center, GZA ANTWERP BELGIUM, Texas Oncology, University of Kansas Medical Center, University of Kansas Medical Center Department of Internal Medicine,
Abstract
Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.Org: NSABP, Dana-Farber Cancer Institute, University of Michigan Health System Comprehensive Cancer Center, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, The Institute of Cancer Research,
Abstract
Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).Org: The Netherlands Cancer Institute, Erasmus MC Cancer Institute, Netherlands Comprehensive Cancer Organisation (IKNL), Erasmus School of Health Policy & Management, Spaarne Gasthuis,
Abstract
Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial.Org: David Geffen School of Medicine at University of California Los Angeles, Moscow City Oncology Hospital No.62, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, National Taiwan University Hospital,
Abstract
3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR), Universidad Europea de Madrid,
Abstract
AI blood signature in common blood tests for detection of gastric cancer in a cohort of 190,000 individualsOrg: The Hong Kong University of Science and Technology, The Chinese University of Hong Kong, Department of Clinical Oncology, Queen Elizabeth Hospital, Department of Neurosurgery, Prince of Wales Hospital, Department of surgery, Kwong Wah Hospital,
Abstract
Large-scale observational prospective cohort study of a multi-cancer early detection (MCED) test in symptomatic patients referred for cancer investigation.Org: Swansea Bay University Health Board, Oxford University Hospitals NHS Foundation Trust, GRAIL LLC, Department of Oncology, University of Oxford, University of Oxford,
Abstract
Childhood leukemia survival in the US-Mexico border: Building sustainable leukemia care using health systems strengthening models.Org: Hospital General Tijuana/Universidad Autonoma de Baja California, Rady Children's Hospital San Diego, University of California San Diego, St. Jude Children's Research Hospital,
Abstract
Prior authorizations for oral anticancer drugs and delayed prescription fills.Org: Boston, MA, Harvard Medical School,
Abstract
SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors.Org: Department of General Practice and Centre for Cancer Research, NHMRC Clinical Trials Centre, Centre for Health Economics Research and Evaluation, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Wellness and Research Centre,
Abstract
Remote symptom-monitoring of patients with advanced lung cancer: A Danish national randomized controlled trial—The ProWide study.Org: Regional Hospital West Jutland, Denmark, Rigshospitalet, Copenhagen, AmbuFlex/WestChronic,
Abstract
WITHDRAWN: A phase 0/1b study of AZD1390 plus radiotherapy in patients with recurrent glioblastoma.Org: Barrow Neurological Institute, Ivy Brain Tumor Center,
Abstract
Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.Org: Department of Neurosurgery, Prince of Wales Hospital, Department of Radiation Oncology, Baptist Health South Florida, Perelman School of Medicine, Department of Radiology,
Abstract
WITHDRAWN: A phase II study analyzing pre-operative stereotactic radiosurgery followed by resection for patients with 1-4 brain metastases.Org: Simon Cancer Center, Indianapolis, IN, Department of Radiation Oncology, Indiana University School of Medicine, Department of Clinical Radiology and Imaging Sciences,
Abstract
PD1 inhibition and GITR agonism in combination with fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma: A phase 2, multi-arm study.Org: University of Pennsylvania, Hospital of the University of Pennsylvania,
Abstract
INB-200 phase I study of gene modified autologous gamma-delta (γδ) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ).Org: In8bio, University of Alabama at Birmingham Comprehensive Cancer Center, In8bio, Inc, In8Bio, Inc.,
Abstract
Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL).Org: START Madrid-CIOCC/University Hospital Sanchinarro, Early Drug Development Group, Division of Medical Oncology, National Cancer Center Singapore, Medical Oncology Department, CatalYm,
Abstract
Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.Org: Flatiron Health, San Francisco, CA, Foundation Medicine, Inc., Cambridge, MA, Foundation Medicine Inc, Morrisville, NC, Flatiron Health, New York, NY, Flatiron Health, Dallas, TX,
Abstract
Analysis of patient-physician portal secure message content and the associated cost savings in oncology practice.Org: San Francisco Medical Center, San Francisco, CA, Kaiser Permanente Northern California, San Rafael Medical Center, The Permanente Medical Group Consulting Services,
Abstract
Observational prospective study of physical activity in patients with cancer to define an objective performance status (OPS).Org: University Hospital Fundacion Jimenez Diaz, Early Phase Clinical Trials Unit, Department of Statistics, University Hospital “Fundacion Jimenez Diaz”, Fundacion Jimenez Diaz University Hospital,
Abstract
A cognitive behavioral digital therapeutic for anxiety and depression in patients with cancer: A decentralized randomized controlled trial.Org: Blue Note Therapeutics, University of Miami Health System, King’s College London,
Abstract
Phase II study of short course hypofractionated proton beam therapy incorporating 18F-DOPA-PET/MRI for elderly patients with newly diagnosed glioblastoma.Org: Mayo Clinic Arizona, Azidus Brasil, Jacksonville, Mayo Clinic, Phoenix Tissue Repair,
Abstract
Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study.Org: Hôpital Saint-Louis, Paris, France, Early clinical unit CLIP2 INCA, Centre GF LECLERC, Dijon, France, department of neurology, AP-HP, Saint Louis Hospital, Paris, France, Department of Radiotherapy, Hôpital du Nord Franche Comté, Montbeliard, France, department of neurology, AP-HP, Saint Louis Hospital, Paris Cité University, Paris, France,
Abstract
Phase II trial of pembrolizumab in patients with brain metastases.Org: Massachusetts General Hospital and Harvard Medical School, Dana-Farber Cancer Institute, Dana-Farber/Brigham and Women's Cancer Center, Massachusetts General Hospital, Yale University,
Abstract
Belzutifan treatment for von Hippel-Lindau (VHL) disease–associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study.Org: Massachusetts General Hospital Cancer Center and Harvard Medical School, Vanderbilt University Medical Center, University of Utah, Department of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Merck & Co., Inc.,
Abstract
Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.Org: The University of Texas MD Anderson Cancer Center, Hospital Universitario 12 de Octubre, NCT Heidelberg, Charité Universitätsmedizin Berlin, Prisma Health Cancer Institute,
Abstract
Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.Org: Department of Bio-therapeutic, Chinese PLA General Hospital, Department of Clinical Research & Development, Shanghai, China, Changzhou, China,
Abstract
BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.Org: Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou JOYO Pharma, China National Biotec Group, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,
Abstract
Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).Org: UC San Diego Moores Cancer Center, National Cancer Institute/National Institutes of Health, Medical College of Wisconsin and WIN Consortium, Fred Hutchinson Cancer Center, Northwestern University,
Abstract
Interim update of the ATRC-101 phase 1b trial in advanced solid tumors.Org: Stephenson Cancer Center, The Tisch Cancer Institute, Mayo Clinic Cancer Center Scottsdale, The University of Arizona Cancer Center, City of Hope Comprehensive Cancer Center,
Abstract
Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.Org: Centre Léon Bérard, Centre Hospitalier de l'Ardenne - Site de Libramont, Centre Oscar Lambret, Institut Curie, Saint Cloud, France, CHU Liège and Liège University,
Abstract
First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer.Org: Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Next Oncology Virginia and Virginia Cancer Specialists, AbbVie Inc., Sarah Cannon Research Institute at Tennessee Oncology, PLLC,
Abstract
Detection of peritoneal metastases during cytoreductive surgery using pegsitacianine, a pH sensitive imaging agent: Final results from a phase 2 study.Org: Wake Forest University Department of General Internal Medicine, Wake Forest Baptist Health, University of Pennsylvania, OncoNano Medicine, Allegheny Health Network Cancer Institute,
Abstract
Methylated DNA biomarkers and incident cancer in the American Cancer Society (ACS) Cancer Prevention Study-3 (CPS-3) cohort.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Independent Statistical Consultant, UCL Hospitals, American Cancer Society, Illumina, Inc.,
Abstract
Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies.Org: Early Phase Clinical Trials Unit and Thoracic Unit, Institut Bergonié, Bordeaux, France, Bergonie Institute, Inserm CIC1401, Bordeaux, France, Institut Bergonié, Molecular Biology Department, Bordeaux, France, Molecular Pathology Unit-Department of Biopathology, Institut Bergonié, Bordeaux, France, Institut Bergonie, Molecular Biology Department, Bordeaux, France,
Abstract
Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.Org: Sylvester Comprehensive Cancer Center, University of Miami Health System, The University of Texas MD Anderson Cancer Center, HonorHealth Research Institute, University of California, San Francisco, Baylor College of Medicine,
Abstract
A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors.Org: Guangdong Lung Cancer Institute, Southern Medical University, First Affiliated Hospital of Zhengzhou University, Shanxi Cancer Hospital, The First Affiliated Hospital/School of Clinical Medicine Guangdong Pharmaceutical University,
Abstract
A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM).Org: Prelude Therapeutics Incorporated, Washington University School of Medicine, Sarah Cannon Research Institute at HealthONE, Florida Cancer Specialists/Sarah Cannon Research Institute, Prelude Therapeutics, Inc.,
Abstract
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.Org: Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Maria Sklodowska-Curie National Research Institute and Oncology Centre (MSCI), Warsaw, Poland, Hospital Clínico San Carlos and IdISSC, Madrid, Spain,
Abstract
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.Org: Daiichi Sankyo Co, Ltd., Daiichi Sankyo Inc.,
Abstract
FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.Org: Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli–IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, Pisa, Italy, Department of Oncology and Palliative Care, Cardinale G Panico, Tricase City Hospital, Tricase, Italy,
Abstract
NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study.Org: Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan, Department of Medical Oncology, Kochi Medical School, Nankoku-City, Japan, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan,
Abstract
Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.Org: Medical Department, Oncology Therapeutic Development, Charité Universitätsmedizin Berlin, Comprehensive Cancer Center at Ludwig Maximilian University of Munich, MVZ Gesundheitszentrum St. Marien GmbH,
Abstract
Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.Org: Danish Colorectal Cancer Center South, Vejle Hospital, Gastro Unit, Department of Oncology, National Taiwan University Hospital, Department of Oncology and Palliative Units,
Abstract
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.Org: Medical Oncology Department, Rene Gauducheau Cancer Center, Institut De Cancerologie D'Ouest Centre Paul Papin, Hôpital Saint Grégoire, Faculté de Médecine Paris-Sud,
Abstract
Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial.Org: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, The 6th Affiliated Hospital, Collaborative Innovation Center for Cancer Medicine,
Abstract
Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC).Org: Asan Medical Center, University of California Los Angeles, University of California Irvine, Hannover Medical School, Zhongshan Hospital,
Abstract
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).Org: Humanity and Health Clinical Trial Center, Liver Unit and HPB Oncology Area, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Barcelona Clinic Liver Cancer,
Abstract
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.Org: Memorial Sloan Kettering Cancer Center, Azienda Ospedaliera Universitaria Integrata di Verona, Hospital Universitario Miguel Servet, Centre Léon Bérard, Masaryk Memorial Cancer Institute,
Abstract
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial.Org: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Department of Radiology, Fudan University Shanghai Cancer Center, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital,
Abstract
Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial.Org: Fujian Medical University Union Hospital, Fuzhou, China, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Ruijin Hospital North, Shanghai Jiao Tong University School of Medcine, Shanghai, China, Dongguan Kang Hua Hospitcal, Dongguan, China, The Sixth Affiliated Hospital of Sun Yat-Sen, Guangzhou, China,
Abstract
Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.Org: Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Division of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan, Research and Development Center for Medical Education, Department of Clinical Skills Education, Kitasato University School of Medicine, Sagamihara, Japan, Division of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo, Japan,
Abstract
ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.Org: Shizuoka Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Beijing Cancer Hospital, Department of Oncology, National Taiwan University Hospital,
Abstract
Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.Org: Sun Yat-sen University Cancer Center, MD Anderson Cancer Center, UT Southwestern Medical Center, Genentech, Roche (China) Holding Ltd.,
Abstract
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC).Org: Zymeworks BC, BeiGene Ltd.,
Abstract
Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1).Org: Institute of Clinical Medicine, University of Oslo, Institute of Clinical Sciences, Department of Surgery, The Sahlgrenska Academy, University of Gothenburg, Department of Biomedical and Clinical Sciences, Linköping University, Clatterbridge Cancer Centre NHS FT, School of Health Sciences, University of Skövde,
Abstract
Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.Org: Gregorio Marañón University General Hospital, IRCCS Istituto Romagnolo per lo Studio dei Tumori, Institute of Oncology Ljubljana, Roche Products Limited, Roche,
Abstract
Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.Org: Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London, United Kingdom, Department of Urology, Chonnam National University Medical School, Gwangju, South Korea, Janssen Research & Development, Spring House, PA, Gustave Roussy and Paris Saclay University, Villejuif, France, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.Org: Memorial Sloan Kettering Cancer Center, Niigata University Graduate School of Medical and Dental Sciences, ICON Research, Bristol Myers Squibb, West-German Cancer Center Essen,
Abstract
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.Org: Dana-Farber Cancer Institute, Gustave Roussy Cancer Center, Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 de Octubre,
Abstract
Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL.Org: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital,
Abstract
Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study.Org: National Cancer Center Hospital Japan East, St. Marianna University School of Medicine, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Seoul National University College of Medicine, HonorHealth Research Institute,
Abstract
Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).Org: Memorial Sloan Kettering Cancer Center, Kyushu University, University Hospital Essen, P.A. Herzen Moscow Oncological Research Institute, University of Miami Sylvester Comprehensive Cancer Center,
Abstract
Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.Org: Cleveland Clinic Lerner College of Medicine, University of California San Diego, Yale Cancer Center, University of California, San Francisco Medical Center, Stanford University School of Medicine, Division of Oncology,
Abstract
SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.Org: UT Health San Antonio, San Antonio, TX, The Ohio State University, Columbus, OH, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, University of Chicago Medical Center, Chicago, IL, SWOG Cancer Research Network, San Antonio, TX,
Abstract
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.Org: Vanderbilt-Ingram Cancer Center, Russian Scientific Center of Roentgenoradiology, Central Clinical Hospital With Outpatient Clinic, Centre Hospitalier de l’Université de Montréal, Hospital de Clínicas de Porto Alegre,
Abstract
Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.Org: Rouen University Hospital, Léon Bérard Cancer Center, Jean Perrin Cancer Center, Centre Eugene Marquis, Francois Baclesse Cancer Center,
Abstract
Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.Org: Dana-Farber Cancer Institute, St. Luke’s Hospital, Division of Urology, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Tor Vergata University of Rome,
Abstract
Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first‑line (1L) treatment stratified by BRCA status.Org: Janssen, Janssen Pharmaceuticals, Janssen Research & Development, Janssen-Cilag B.V., Janssen Pharmaceutica NV,
Abstract
Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC ≤3cm: Combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne.Org: St. Olav's University Hospital, Karolinska University Hospital, Institute of Clinical Sciences, Karolinska Institutet, University Hospital UMAS,
Abstract
In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.Org: Centre Léon Bérard, School of Medicine, Showa University, Centre François Baclesse, Groupe Hospitalier Diaconesses Croix Saint-Simon, Institut Claudius Regaud, IUCT-Oncopole, CRCT, lnserm, Toulouse, France,
Abstract
Association of medical debt and cancer mortality in the US.Org: American Cancer Society, Emory University School of Public Health,
Abstract
Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG/RTOG trials.Org: Artera, Vancouver, BC, Canada, Department of Pathology, University of California San Francisco, San Francisco, CA, Tulane University, New Orleans, LA, University of California, San Francisco, San Francisco, CA, Case Western Reserve University, Cleveland, OH,
Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.Org: University of Paris-Saclay, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Kashiwa, Japan, Vall d’Hebron University Hospital/VHIO, Barcelona, Spain,
Abstract
LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).Org: Sir Peter MacCallum Department of Oncology, St. Vincent's Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Radiation Oncology, St. Vincent's Medical School,
Abstract
Long term follow-up analysis of plasma miR371 expression to detect early relapse in patients with clinical stage I testicular germ cell tumors on surveillance.Org: Department of Urologic Sciences, Vancouver General Hospital, Canada, BC Cancer - Vancouver Centre, BC,
Abstract
The genomic and transcriptomic landscapes of chemotherapy naïve vs post-chemotherapy germ cell tumors.Org: University of California San Diego Health, CanSino Biologics, La Jolla, CA, UT Southwestern Medical Center, Txinno Bioscience,
Abstract
Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.Org: Gustave Roussy Institute, Bergonié Institute, Léon Bérard Cancer Center, Institut de Cancérologie de l'Ouest, Azuréen Center of Oncology,
Abstract
KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.Org: University of Arizona College of Medicine, European Institute of Oncology IRCCS, University of California Irvine, GINECO-Centre Jean Perrin, Clermont-Ferrand, France, Saitama Medical University International Medical Center,
Abstract
Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).Org: US Oncology Research, HonorHealth Research Institute, Creighton University School of Medicine, The Ohio State University James Cancer Center, Division of Gynecologic Oncology,
Abstract
Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.Org: Copenhagen University Hospital, Washington University School of Medicine, ModernaTX, Rigshospitalet, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit,
Abstract
Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).Org: HonorHealth Research Institute, Duke Cancer Institute, Chaim Sheba Medical Center, University of Cincinnati Cancer Institute, International Drug Development Institute,
Abstract
Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.Org: O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham School of Medicine, Clinical Trial Development Division, Roswell Park Comprehensive Cancer Center, Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute, University of Oklahoma Health Sciences Center,
Abstract
Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.Org: Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, The Ohio State University James Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University, University of Chicago,
Abstract
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.Org: Sun Yat-sen University Cancer Centre, Collaborative Innovation Centre for Cancer Medicine, Hunan Cancer Hospital, Department of Radiation Oncology, Affiliated Hospital of Guizhou Medical University,
Abstract
Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.Org: Sun Yat-sen University Cancer Center, Clinical Research Design Division, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Nanfang Hospital, Sun Yat-sen Memorial Hospital,
Abstract
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.Org: Agomab Spain, LMU Munich, The Jikei University School of Medicine, Co-ordinating Center for Clinical Trials of the Philipps-University of Marburg, Seoul National University Hospital,
Abstract
Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.Org: Centre Léon Bérard, Centre Paul Strauss, CH Bretagne, Centre Henri Becquerel, Clinique des Ormeaux,
Abstract
Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.Org: Dana-Farber Cancer Institute, UPMC Hillman Cancer Center, Cleveland Clinic Lerner College of Medicine, Princess Margaret Cancer Centre, Moffitt Cancer Center,
Abstract
Randomised phase III trial of the hypoxia modifier nimorazole added to radiotherapy with benefit assessed in hypoxic head and neck cancers determined using a gene signature (NIMRAD).Org: Velindre Cancer Centre, Beatson West of Scotland Cancer Centre, National Radiotherapy Trials Quality Assurance (RTTQA) Group, Systems Forecasting Ltd,
Abstract
Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.Org: University of Chicago Department of Surgery, University of Chicago Medical Center, Chicago, IL, Department of Medicine, University of Chicago, Department of Radiation and Cellular Oncology, Rush University Medical Center,
Abstract
Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results.Org: The University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Thoracic/Head and Neck Medical Oncology, Houston, TX,
Abstract
PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).Org: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Guizhou Cancer Hospital, Guiyang, China, Affiliated Tumor Hospital of Guangxi Medical University, Guangxi, China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Xijing Hospital, Xi'an, China,
Abstract
Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).Org: Narayana Multispeciality Hospital, Tata Memorial Hospital, Homi Bhabha cancer hospital and research centre, Regency Hospital, National Cancer Insitute,
Abstract
Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.Org: University College London Cancer Institute, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, Manchester Royal Infirmary, Texas Transplant Physician Grp, PLLC,
Abstract
Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.Org: University of Chicago, H. Lee Moffitt Cancer Center and Research Institute, City of Hope National Medical Center, University of Washington/Fred Hutchinson Cancer Research Center, University of Colorado Cancer Center,
Abstract
Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)‑naive transfusion-dependent (TD) patients (pts) with lower‑risk myelodysplastic syndromes (LR-MDS).Org: University of Texas M.D. Anderson Cancer Center, Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, University of Florence, AOUC, Yale School of Medicine and Yale Cancer Center, Yale University, Monash University and Monash Health,
Abstract
A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.Org: City of Hope National Medical Center, Erasmus University Medical Center, Institut Paoli-Calmettes, Marseille, France, University Medical Center Groningen, MD Anderson Cancer Center,
Abstract
Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8).Org: Sun Yat-sen University Cancer Center (China), Rui Jin Hospital Affiliated to Shanghai Jiao Tong University, Jinagsu Province Institute of Cancer Research, The University of Texas MD Anderson Cancer Center, Chongqing University Cancer Hospital,
Abstract
A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia/lymphoma.Org: National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, Nagoya City University Graduate School of Medical Sciences, Imamura General Hospital, Kumamoto University Hospital, Kindai University Faculty of Medicine, Osaka-Sayama, Japan,
Abstract
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.Org: Dana-Farber Cancer Institute, Institut Català D'Oncologia, Leiden University Medical Center, Rigshospitalet, Copenhagen University Hospital, Ronald Reagan University of California Los Angeles Medical Center,
Abstract
Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.Org: City of Hope National Medical Center, Center for International Blood and Marrow Transplant Research, University of North Carolina School of Medicine, Moffitt Cancer Center, Stanford University Hospital,
Abstract
Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.Org: Institut Curie, Saint Cloud, France, Hemato-oncology, IUCT-Oncopole Toulouse, Department of Hemagology, Centre François Magendie,
Abstract
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study.Org: Schleswig-Holstein University Hospital, Hospital Salzburg Paracelus University, University Hospital rechts der Isar, Jena University Hospital, Wuerzburg University Medical Center,
Abstract
Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): A phase 2 study with a safety run-in.Org: Winship Cancer Center of Emory University, Emory University, Atlanta, GA, USA, Emory University School of Medicine, Biostatistics Shared Resource, Winship Cancer Institute of Emory University,
Abstract
Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.Org: Vanderbilt University Medical Center, University Hospital of Salamanca, Helen Diller Family Comprehensive Cancer Center, Princess Margaret Cancer Centre, Levine Cancer Institute/Atrium Health,
Abstract
LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.Org: Karmanos Cancer Institute, Ziekenhuis Netwerk Antwerpen Stuivenberg, Regeneron Pharmaceuticals, Inc.,
Abstract
IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).Org: Yale School of Medicine and Yale Cancer Center, Yale University, Leipzig University Hospital, Azienda Ospedaliero Universitaria Careggi, University of Florence, Hôpital Saint-Louis, Université de Paris, Sylvester Comprehensive Cancer Center, University of Miami Health System,
Abstract
Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.Org: Alliance Statistics and Data Management Center, Rochester, MN, University of Chicago, Chicago, IL, Georgetown University Hospital, Washington, DC, Helen F. Graham Cancer Center and Research Institute, Newark, DE, University of North Carolina, Chapel Hill, NC,
Abstract
A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL).Org: Fred Hutchinson Cancer Center, University of Washington/Fred Hutchinson Cancer Center,
Abstract
Specialty cancer care and survival in AYA ALL: A U.S. multi-state analysis.Org: Stanford University, Stanford, CA, University of Minnesota, Minneapolis, MN, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, University of California Davis, Sacramento, CA,
Abstract
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).Org: Alliance Statistics and Data Management Center, Alliance Protocol Operations Office, Illinois CancerCare, Mayo Clinic, Trinity Health Saint Joseph Mercy Hospital,
Abstract
Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004.Org: Fred Hutchinson Cancer Center, Duke University Health System, Center for Lymphoma, University of Chicago Medical Center, Chicago, IL, Banner MD Anderson Cancer Center,
Abstract
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.Org: Niguarda Cancer Center, Laboratory of Experimental Hematology, Clinic of Hematology, Ente Ospedaliero Cantonale, Universita’ della Svizzera italiana,
Abstract
First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Org: Sackler School of Medicine, Hospital Universitario Fundación Jiménez Díaz, McGill University and MUHC, Sungkyunkwan University School of Medicine, Hospital Germans Trias i Pujol,
Abstract
Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).Org: University of Chicago, Novartis Institutes for BioMedical Research, Medical College of Wisconsin, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center,
Abstract
Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).Org: Gracell Biotechnologies Ltd,
Abstract
A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM‑3.Org: Clinica São Germano, São Paulo, Brazil, General Hospital Evangelismos, Athens, Greece, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary, Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil, GSK, Upper Providence, PA,
Abstract
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.Org: Weill Cornell Medical College - New York Presbyterian Hospital, Fox Chase Cancer Center, Arnie Charbonneau Cancer Institute, University of Calgary, Massachusetts General Hospital Cancer Center, Pfizer SLU,
Abstract
Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.Org: Oncology Institute of Southern Switzerland, Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland, University of Southampton,
Abstract
Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.Org: Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Memorial Sloan Kettering Cancer Center, Vall d’Hebron University Hospital/VHIO, Lausanne University Hospital, William Osler Health System,
Abstract
Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results.Org: Zhejiang Cancer Hospital, Hangzhou, China, Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China, The First Hospital of China Medical University, Shenyang, China, The Affiliated Cancer Hospital of Xinjiang Medical University, Wulumuqi, China, Second Affiliated Hospital of Nanchang University, Nanchang, China,
Abstract
The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).Org: Kumamoto University Hospital, Kurume University School of Medicine, Kitakyushu Municipal Medical Center, Wakayama Medical University, Wakayama, Japan, Internal Medicine III, Wakayama Medical University,
Abstract
Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.Org: Miami Cancer Institute, Poznan University of Medical Sciences, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, General University Hospital in Prague,
Abstract
Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).Org: The University of Sydney, University of Pittsburgh Medical Center, Medical University of Vienna, Perlmutter Cancer Center at NYU Langone Health Medical Center, Elbe Klinikum Buxtehude,
Abstract
Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.Org: Key Laboratory of Carcinogenesis and Translational Research, Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Department of Melanoma and Sarcoma,
Abstract
Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).Org: New York University School of Medicine, The Ohio State University Comprehensive Cancer Center, Duke University Medical Center, Northwestern University, University of Colorado Comprehensive Cancer Center,
Abstract
Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: Findings from the prospective, randomized, multicentric phase II study NEOpredict-Lung.Org: West German Cancer Center, University Hospital Essen, Jessa Hospital, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Pathology and Neuropathology,
Abstract
Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.Org: Shanghai Chest Hospital, Hunan Cancer Hospital, Department of Pulmonary Medicine, Department of Thoracic Surgery and Oncology, Cancer Hospital of the University of Chinese Academy of Sciences,
Abstract
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).Org: Technical University Dresden, Medical Faculty, NCT/UCC Early Clinical Trial Unit, Department of Medical Oncology, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology, Washington University School of Medicine, Department of Immunology and Oncology, Clínica Universidad de Navarra, Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques),
Abstract
SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).Org: University of Virginia, Charlottesville, VA, USA, Fred Hutchinson Cancer Research Center, Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Levine Cancer Institute,
Abstract
Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.Org: University of Leicester and Leicester University Hospitals, University of Southampton, Harry Perkins Institute of Medical Research, Perth, Australia, Liverpool, United Kingdom,
Abstract
Association of somatic mutations and histologic subtype/grade on prognosis and PD-L1 expression in mesothelioma.Org: University of Chicago, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, University of Chicago Bucksbaum Institute for Clinical Excellence, Section of Hematology/Oncology, The University of Chicago Medicine,
Abstract
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.Org: Guangdong Lung Cancer Institute, China National Biotec Group, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou JOYO Pharma, Cancer Hospital,
Abstract
Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.Org: State Key Laboratory of Molecular Oncology, National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Chest Hospital, Capital Medical University, Beijing, China, Liaoning Cancer Hospital,
Abstract
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).Org: National Cancer Center Hospital East, Kashiwa, Japan, National Cheng Kung University, Daiichi Sankyo Inc., Taichung Veterans General Hospital, Mayo Clinic,
Abstract
KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).Org: University Hospitals Leuven, Leuven, Belgium, Vall d’Hebron University Hospital/VHIO, Department of Oncology, National Taiwan University Hospital, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Centre Singapore,
Abstract
Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).Org: Netherlands Cancer Institute, Henry Dunant Hospital, Universitätsspital Zürich, University of Texas MD Anderson Cancer Center, Hospital Universitario 12 de Octubre,
Abstract
IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.Org: Cross Cancer Institute, Assistance Publique Hôpitaux de Marseille (AP-HM), Fondazione IRCCS Istituto Nazionale Tumori, AZ Ospedaliera Villa Scassi, National Cancer Institute of Naples,
Abstract
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.Org: National Taiwan University Hospital and National Taiwan University Cancer Center, Seoul National University Bundang Hospital, Istituto Europeo di Oncologia, Osaka International Cancer Institute, Osaka, Japan, Peking Union Medical College Hospital,
Abstract
Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.Org: The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, Henry Ford Cancer Institute, Detroit, MI, START San Antonio, San Antonio, TX, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, MUSC Hollings Cancer Center, Charleston, SC,
Abstract
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.Org: University of Texas MD Anderson Cancer Center, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, University Duisburg-Essen, German Cancer Consortium, Instituto Oncológico Fundación Arturo López Pérez,
Abstract
Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic Merkel cell carcinoma (MCC) (CheckMate 358).Org: Division of Medical Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, UCL Cancer Center, University College London, London, United Kingdom, Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan,
Abstract
Towards organ preservation and cure via 2 infusions of immunotherapy only, in patients normally undergoing extensive and mutilating curative surgery for cutaneous squamous cell carcinoma: An investigator-initiated randomized phase II trial—The MATISSE trial.Org: Netherlands Cancer Institute (NKI-AVL), Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, The Netherlands Cancer Institute, University Medical Cancer Center Utrecht, Netherlands Cancer Institute,
Abstract
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.Org: Laura and Isaac Perlmutter Cancer Center, Sir Charles Gairdner Hospital, Washington University Oncology, Sarah Cannon Research Institute/Tennessee Oncology, One Clinical Research and Edith Cowan University,
Abstract
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.Org: Istituto Nazionale Tumori IRCCS Fondazione Pascale, Hospital Universitario Virgen Macarena, Maria Skłodowska-Curie National Institute of Oncology Center, Poznan University of Medical Sciences and Greater Poland Cancer Center, UPMC Hillman Cancer Center,
Abstract
High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial.Org: Children’s Cancer Research Institute (CCRI), St. Anna Kinderkrebsforschung GmbH, Schneider Children‘s Medical Center of Israel, Sackler Faculty of Medicine Tel Aviv University, Paediatric Haematology Oncology, Jagiellonian University Medical College, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital, Karolinska Institutet, Childhood Cancer Research Unit,
Abstract
Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial.Org: University Hospital of Regensburg, University Medicine Greifswald, Pediatric Hematology and Oncology, University Medical Center Dresden, University of Jena, University Children's Hospital,
Abstract
A multicenter cooperative group study of late effects after high-risk neuroblastoma: COG ALTE15N2—LEAHRN study.Org: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, St. Jude Children's Research Hospital, Children's Oncology Group Statistics and Data Center, University of Florida, Children's Hospital Los Angeles Department of Pediatrics,
Abstract
Biological Medicines for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (BIOMEDE): Final results of an international randomized phase II platform trial comparing 3 targeted therapies in combination with radiotherapy from ITCC, SIOPE-Brain and ANZCHOG.Org: Gustave Roussy Cancer Centre, University College London Hospital NHS Trust and Great Ormond Street Hospital, Department of Women's and Children's Health, Princess Maxima Center, Necker Hospital,
Abstract
Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study.Org: Children's National Hospital, Washington, DC, Duke University, Durham, NC, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX,
Abstract
Treatment of focal anaplastic Wilms tumor (FAWT): A report from the Children’s Oncology Group (COG) AREN0321 and AREN03B2 studies.Org: Washington University in St Louis, University of Southern California, Los Angeles, CA, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Michigan Hospital, Uniformed Services University of the Health Sciences,
Abstract
Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG Pediatric MATCH trial Arm I (APEC1621I).Org: Department of Pediatrics, University of Colorado and Center for Cancer and Blood Disorders, Children’s Hospital Colorado, Aurora, CO, University of Michigan, Ann Arbor, MI, Mayo Clinic, Rochester, MN, Children's Oncology Group, Monrovia, CA, Univ of Southern California/Children's Oncology Group, Arcadia, CA, Texas Children's Cancer and Hematology Center, Houston, TX, St. Jude Children's Research Hospital, Memphis, TN, Seattle Children's Hospital, Seattle, WA, National Cancer Institute, Rockville, MD, Frederick National Laboratory for Cancer Research, Frederick, MD, Center for Biomedical Informatics & Information Technology, NCI, NIH, Bethesda, MD, MD Anderson Cancer Center, Houston, TX, Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, National Cancer Institute Center for Bioinformatics, Rockville, MD, Dana-Farber Cancer Institute, Boston, MA, Cancer Therapy Evaluation Program, NCI, Bethesda, MD, Texas Children's Cancer Center/Baylor College of Medicine, Houston, TX,
Abstract
Feasibility of the Poverty-Targeted Pediatric Cancer Resource Equity (PediCARE) intervention.Org: Children's Hospital of Philadelphia, DFCI/PCC Fellowship Program - Attendings, Dana-Farber Cancer Institute, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, University of Alabama at Birmingham,
Abstract
Feasibility and acceptability of social determinants of health data collection in the context of a Children’s Oncology Group trial.Org: Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, UCSF Benioff Children's Hospital, Children's Hospital of Philadelphia, Children's Oncology Group Statistics and Data Center, University of Florida, University of Minnesota,
Abstract
Enhancing prediction of cancer therapy-related cardiomyopathy from surveillance echocardiograms: A Children’s Oncology Group (COG) report.Org: City of Hope National Medical Center, University of Washington School of Medicine, University of Minnesota, Fred Hutchinson Cancer Center, Seattle Children's Hospital,
Abstract
Clonal hematopoiesis in survivors of childhood cancer.Org: New York City, St Louis, Washington University School of Medicine, ModernaTX, St. Louis,
Abstract
Preliminary results from the first-in-child phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML).Org: Prinses Maxima Centrum, Pfizer R&D UK Ltd, IRCCS Bambino Gesù Children’s Hospital, Erasmus MC Cancer Institute, Hematologics,
Abstract
Second primary breast cancer in young breast cancer survivors.Org: Harvard School of Public Health, Beth Israel Deaconess Medical Center and Harvard Medical School, Stanford Comprehensive Cancer Institute, Odette Cancer Centre, Beth Israel Deaconess Medical Center,
Abstract
Ancestry-adjusted genomic analysis to identify known and novel associations with single and multiple cancer phenotypes.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).Org: Weill Cornell Medicine, New York, NY, MD Anderson Cancer Center, Houston, TX, National Cancer Institute, Rockville, MD, Children's Oncology Group, Monrovia, CA, Texas Children's Cancer and Hematology Center, Houston, TX,
Abstract
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.Org: Children’s Hospital of Philadelphia, University of Pennsylvania, Children's Oncology Group Statistics and Data Center, University of Florida, CanSino Biologics, Dana Farber Cancer Institute, Boston, MA,
Abstract
Medicaid enrollment changes among U.S. adult survivors of childhood cancer following Medicaid expansion: A report from the Childhood Cancer Survivor Study (CCSS).Org: Atlanta, GA, Seattle, WA, Toronto, ON, Canada, Memphis, TN, Salt Lake City, UT,
Abstract
Carvedilol for prevention of heart failure in anthracycline-exposed survivors of childhood cancer: Results from COG ALTE1621.Org: City of Hope National Medical Center, City of Hope Comprehensive Cancer Center, Boston Children's Hospital, Boston Children's Hospital and Dana-Farber Cancer Institute, St. Jude Children's Research Hospital,
Abstract
Genomic determinants of outcome in acute lymphoblastic leukemia: A Children’s Oncology Group study.Org: St. Jude Children’s Research Hospital, Memphis, TN, The Hospital for Sick Children, Toronto, ON, Canada, Perlmutter Cancer Center and NYU Langone, New York, NY, Children's Hospital of Alabama, Birmingham, AL, Children's Hospital Colorado, Aurora, CO,
Abstract
A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732.Org: Cincinnati Children's Hospital Medical Center, Children's Hospital of Philadelphia, University of Florida Department of Biostatistics, UCSF Benioff Children's Hospital Oakland, Loyola University Medical Center,
Abstract
Germline genetic testing use and results after a cancer diagnosis.Org: Stanford University School of Medicine, Stanford Women's Cancer Center, GeneDx, Myriad Genetics, Stanford Cancer Institute,
Abstract
Breast cancer risk associated with missense variants in BRCA2.Org: Ambry Genetics, Harvard T.H. Chan School of Public Health, Sierra Madre, Abramson Cancer Center, University of Pennsylvania,
Abstract
Incidence round screening performance among women with dense breasts undergoing abbreviated breast MRI and digital breast tomosynthesis (ECOG-ACRIN EA1141).Org: Brown University School of Public Health, Brown University School of Medicine-Rhode Island Hospital, University of Washington School of Medicine, Memorial Sloan Kettering Cancer Center, University of Rochester,
Abstract
Whole exome sequencing and machine learning germline analysis of individuals presenting with phenotypes of extreme high and low risk of developing tobacco-induced lung adenocarcinoma.Org: Center for Applied Medical Reseach (CIMA), Universidad de Navarra - CIMA LAB Diagnostics, Universitat Politècnica de València, University Hospital Carl Gustav Carus, Medical Clinic I, Technical University Dresden, Clinica Universidad de Navarra,
Abstract
Biologic indicators of donor socioeconomic disadvantage and recipient mortality following allogeneic hematopoietic cell transplantation.Org: David Geffen School of Medicine at UCLA, University of Colorado-Denver, University of Minnesota, Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research,
Abstract
Evaluation of potential socioeconomic and racial/ethnic disparities in all-cause mortality in adolescent and young adult patients with cancer.Org: Kaiser Permanente School of Medicine, Kaiser Permanente Northern California, Kaiser Permanente Bernard J. Tyson School of Medicine, Kaiser Permanente Southern California,
Abstract
Health insurance continuity and survival among children, adolescents, and young adults with blood cancer: An analysis based on SEER-Medicaid data.Org: Emory University Rollins School of Public Health, American Cancer Society, Emory University School of Medicine, Center for Data Intensive Science at the University of Chicago,
Abstract
Polygenic risk score calibration and association with breast cancer in diverse ancestries.Org: Myriad Genetics, Inc., Vanderbilt University Medical Center, Abramson Cancer Center, University of Pennsylvania, Providence Health/St John Cancer Institute, Memorial Sloan Kettering Cancer Center,
Abstract
Integrating polygenic risk scores into clinical breast cancer models: Influence on prediction in diverse cohorts.Org: Allelica Inc, Rome, Nykode Therapeutics, Hartford Healthcare Cancer Institute, Italy,
Abstract
Lung cancer metabolomics: A pooled analysis in the Cancer Prevention Studies.Org: Emory University, Atlanta, GA, USA, Galderma R&D, Kennesaw, American Cancer Society - BrightEdge, Atlanta, GA,
Abstract
Disparities in outcomes among hospitalized unhoused patients with cancer in the US.Org: NYU Grossman School of Medicine, Department of Radiation Oncology, Tufts University School of Medicine, Memorial Sloan Kettering Cancer Center, Washington University School of Medicine in St. Louis,
Abstract
Risk of early mortality in patients with cancer experiencing adverse financial events.Org: University of Washington/Fred Hutch Cancer Center, University of Washington School of Medicine, University of Washington, Fred Hutchinson Cancer Center, Fred Hutchinson Cancer Center, Fred Hutchinson Cancer Research Center,
Abstract
Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO).Org: Nashville, OneOncology, TN, South San Francisco, Genentech,
Abstract
A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas.Org: University of Colorado School of Medicine, University of Colorado Denver, Agenus, University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center,
Abstract
ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma.Org: Medical Oncology Department, Institute of Biomedicine of Seville, Hospital Universitario y Politécnico La Fe, Son Espases University Hospital, University Hospital Virgen del Rocio,
Abstract
A phase III randomized trial of neo-adjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STS 1001): Feasibility and activity of concurrent chemotherapy and radiation therapy.Org: Fondazione IRCCS Istituto Nazionale dei Tumori, IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Humanitas Clinical Institute, Candiolo Cancer Institute, Centre Léon Bérard,
Abstract
Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS).Org: MGH Cancer Center, Massachusetts General Hospital, Mayo Clinic, Ludwig Center at Harvard Medical School, Dana-Farber Cancer Institute,
Abstract
Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort.Org: Memorial Sloan Kettering Cancer Center, Knight Cancer Institute, University of Iowa Carver College of Medicine, University of Michigan Rogel Comprehensive Cancer Center, Sarcoma Oncology Center,
Abstract
Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.Org: Washington University Siteman Cancer Center, St. Louis, MO, Washington University School of Medicine, Washington University in Saint Louis, University of Colorado Cancer Center, University of Pennsylvania-Abramson Cancer Center,
Abstract
Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.Org: Weill Cornell Medicine, Mount Sinai Hospital-Breast Medical Oncology, Massachusetts General Hospital, UM/Sylvester Comprehensive Cancer Center, UNC Patient Advocates for Research Council,
Abstract
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.Org: Durham, NC, Labcorp Oncology, Nykode Therapeutics, Buffalo, Duke University Medical Center,
Abstract
Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the community setting.Org: The West Cancer Center, OneOncology, Foundation Medicine, Inc., Cambridge, MA, Genentech Inc., Flatiron Health, San Francisco, CA,
Abstract
Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc).Org: Helios Klinikum Berlin-Buch, Charité–Universitätsmedizin Berlin, Medizinische Fakultät “Carl Gustav Carus“ der TU Dresden, Universitätsklinikum Würzburg, Universität Heidelberg,
Abstract
A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).Org: Duke University Medical Center, Mayo Clinic, Vanderbilt University Medical Center, Virginia Commonwealth University Health System, Duke Cancer Institute,
Abstract
A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas.Org: Mayo Clinic, Northwestern University, UCSF Helen Diller Family Comprehensive Cancer Center, University of Iowa, City of Hope National Medical Center,
Abstract
Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).Org: Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan, Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Medical Oncology Department, Institut de Cancérologie du Gard - CHU Caremeau, Nimes, France, Department of Medical Oncology, Centre Eugene Marquis, Rennes, France, Seoul National University Hospital, Seoul, Korea, Republic of (South),
Abstract
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.Org: University of Milan-Bicocca, University of California Los Angeles Medical Center, European Institute of Oncology IRCCS, University of Chicago, ImmunoGen,
Abstract
A multicenter randomized controlled trial (RCT) for the effectiveness of Comprehensive Geriatric Assessment (CGA) with extensive patient coaching on quality of life (QoL) in older patients with solid tumors receiving systemic therapy: G-oncoCOACH study.Org: University Hospitals Leuven, Leuven, Belgium, Academic Centre for Nursing and Midwifery, Universitair Ziekenhuis Brussel, European Medicines Agency, Department of Public Health and Primary Care,
Abstract
Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine.Org: All India Institute of Medical Sciences, Dr. Brairch, Abbisko Therapeutics, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, All India Institute of Medical Science (AIIMS),
Abstract
Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice: Results from WF-1804CD.Org: University of Kansas School of Medicine, Wake Forest School of Medicine, Mercy Hospital Springfield, Washington University School of Medicine Saint Louis, Washington University in St. Louis School of Medicine,
Abstract
Results of a tailored multimodal lifestyle follow-up care program focusing on physical activity, nutritional behavior and psychological processes in adolescent and young adult cancer survivors: The CARE for CAYA multicenter, randomized clinical trial.Org: University Cancer Center Hamburg, Universitätsklinikum Hamburg-Eppendorf, University Hospital Bonn, Department of Internal Medicine I, Medical University of Vienna, Campus Luebeck,
Abstract
Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714.Org: Fred Hutchinson Cancer Research Center, University of Michigan, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP, Bon Secours Cancer Institute at St. Francis, Cancer & Hematology Centers of Western Michigan,
Abstract
Phase 3 randomized placebo-controlled trial of donepezil for late cancer-related cognitive impairment in breast cancer survivors exposed to chemotherapy from the Wake Forest NCORP Research Base REMEMBER trial (WF97116).Org: Heartland NCORP, Minnesota Oncology Hematology PA - Coon Rapids, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Wake Forest University School of Medicine, Oncology Hematology Assoc of SW Indiana,
Abstract
Reduced symptom burden after implementation of an electronic symptom management program.Org: MaineHealth Cancer Care, Department of Medical Oncology, Dana-Farber Cancer Institute, Dartmouth-Hitchcock Medical Center, WVU Cancer Institute, Memorial Sloan Kettering Cancer Center,
Abstract
Telehealth-based psychological intervention for caregivers of patients with primary malignant brain tumors: A randomized controlled trial.Org: Massachusetts General Hospital, Harvard University, Division of Hematology & Oncology, Harvard Medical School, UMass Memorial Cancer Center,
Abstract
Characterization of the immune microenvironment in matched primary and metastatic breast cancer lesions from the AURORA study: BIG 14-01.Org: Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Brussels, Belgium, Fundación Instituto Valenciano de Oncología (FIVO), GEICAM Spanish Breast Cancer Group, Valencia, Spain, Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium, Department of Mathematics, Università degli Studi di Genova, San Martino, Italy,
Abstract
Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).Org: Columbus, OH, GZA-ZNA Hospitals, Joan and Sanford I Weill Medical College of Cornell University, Weill Cornell Medicine, New York, NY,
Abstract
RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial.Org: Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany, Nationales Centrum für Tumorerkrankungen, Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, Germany, Institute of Pathology, Philipps-University Marburg and University Hospital Marburg, Marburg, Germany, Pathologie, Universitätsklinikum Heidelberg, Heidelberg, Germany, Interdisciplinary Breast Center, Rotkreuz-Clinics Munich, Munich, Germany, Goethe-Universität Frankfurt, UCT-Frankfurt-Marburg, Frankfurt, Germany, Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin, Germany, SRH Waldklinikum Gera GmBH, Gera, Germany, Institut für Versorgungsforschung, Koblenz, Germany, Kantonsspital St.Gallen, Brustzentrum, Departement Interdisziplinäre medizinische Dienste, St. Gallen, Switzerland, Gynäkologie, Rotkreuzklinikum München, München, Germany, HELIOS Clinic Berlin-Buch, Berlin, Germany, University Hospital Frankfurt, Frankfurt Am Main, Germany, Department of Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany, German Breast Group GmbH, Neu-Isenburg, Germany, German Breast Group (GBG), Neu-Isenburg, Germany, German Breast Group, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany, Department of Obstetrics and Gynecology, University Hospital Erlangen, Erlangen, Germany,
Abstract
BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.Org: ECOG-ACRIN Biostatistics Center, University Hospitals Seidman Cancer Center, University of Miami Sylvester Cancer Center, Ohio State University Comprehensive Cancer Center, Temple University Health System,
Abstract
Clinical and analytical validation of a targeted gene expression biomarker predicting meningioma outcomes and radiotherapy responses.Org: University of California-San Francisco, University of Chicago Medical Center, Chicago, IL, University of California San Francisco, University Clinic of Heidelberg, UCSF Department of Radiation Oncology,
Abstract
Prognostic evaluation of surgical re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.Org: Department of Neurosurgery, University of Texas, Houston, TX, Department of Neurosurgery, University of Cologne, Cologne, Germany, Division for Neuro-Oncology, Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Turin, Italy, Department of Neurosurgery, Ludwig-Maximilians-University, Munich, Germany,
Abstract
A genomic score to predict local control among patients with brain metastases managed with radiation.Org: Brigham and Women's Hospital, Mater Private Hospital, Dana-Farber Cancer Institute, Broad Institute of Harvard and MIT, Boston, MA,
Abstract
External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma.Org: The University of Texas MD Anderson Cancer Center, The University of Sydney, Melanoma Institute Australia, Royal Prince Alfred Hospital, Sydney, NSW, Australia,
Abstract
Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes.Org: Massachusetts General Hospital, Brigham and Women's Hospital, Newton,
Abstract
First-line treatment of fecal microbiota transplantation for immune-mediated colitis.Org: University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center,
Abstract
An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).Org: University of British Columbia, Vancouver, BC, Canada, Gynecologic Oncology, Centre Hospitalier de l’Université de Montréal (CHUM), Centre de Recherche de l’Université de Montréal (CRCHUM), Université de Montréal, Montreal, QC, Canada, Gustave Roussy Cancer Center, Villejuif, France, Netherlands Cancer Institute, Amsterdam, Netherlands, Innsbruck Medical University; Department of Obstetrics and Gynecology, Innsbruck, Austria,
Abstract
A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study.Org: Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Mibu, Japan, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan, Department of Thoracic Oncology, Aichi Cancer Center, Nagoya, Japan,
Abstract
Differential burnout by race, sex, and sexual orientation in academic oncology.Org: University of Utah, Memorial Sloan Kettering Cancer Center, University of California San Francisco, Association of American Medical Colleges,
Abstract
Diversity, equity, & inclusion (DEI) and health equity (HE) education in hematology/oncology (HO) fellowship: A longitudinal curriculum.Org: Yale Cancer Center, Yale School of Medicine,
Abstract
POT1 germline pathogenic variants and evolving understanding of tumor spectrum: Evidence for lung cancer predisposition.Org: Memorial Sloan Kettering Cancer Center, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS).Org: Princess Margaret Cancer Centre, Department of Pathology and Laboratory Medicine, Radiation Medicine Program, Natera, Inc., University Health Network,
Abstract
Deep learning with whole slides images to predict histological response to neoadjuvant chemotherapy in patients with resectable high grade soft-tissue sarcomas: A multicenter study.Org: OWKIN, Bergonié Institute, Centre Léon Bérard, Institut Bergonié,
Abstract
Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.Org: Gwangju Institute of Science and Technology (GIST), prismCDX Co., Ltd, Asan Institute for Life Sciences, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.Org: City of Hope Comprehensive Cancer Center, CanSino Biologics, Flagstaff, Yale University School of Medicine, CTI BioPharma,
Abstract
Identifying molecular targets for rational immunosuppressive strategies in patients with immune checkpoint therapy-induced myocarditis and myositis.Org: The University of Texas MD Anderson Cancer Center, University of Texas Health Science Center, MD Anderson Cancer Center at Cooper, MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center,
Abstract
Transcriptional metabolic profiling in young onset colorectal cancer (CRC) patients.Org: University of Kentucky, Ohio State University Wexner Medical Center, Ohio State University James Cancer Hospital Department of Radiation Oncology, Roswell Park Comprehensive Cancer Center, Moffitt Cancer Center,
Abstract
Metabolomic differences in young-onset versus average-onset colorectal adenocarcinoma.Org: Cleveland Clinic Lerner College of Medicine, Taussig Cancer Institute, Cleveland Clinic Lerner Research Institute,
Abstract
Evaluation of genomic alterations in early-onset versus late-onset colorectal cancer.Org: Natera, Inc., Natera, Inc, Vanderbilt-Ingram Cancer Center,
Abstract
Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.Org: MSKCC, Cleveland Clinic, Taussig Cancer Center, Fox Chase Cancer Center, Clinica Universidad de Navarra, Karolinska University Hospital,
Abstract
Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).Org: City of Hope Comprehensive Cancer Center, Roche (China) Holding Ltd., Asan Medical Center, Genentech, Roche Products Ltd.,
Abstract
Subgroup analysis of double-blind, placebo-controlled Ph. 2 study of nanvuranlat in treatment of pre-treated, advanced, refractory biliary tract cancer (BTC): Patients with high LAT1 expression and response to nanvuranlat.Org: Kanagawa Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, National Hospital Organization Shikoku Cancer Center, Kyorin University, The University of Tokyo,
Abstract
Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.Org: Biometrics Department, Department of Gynecological Oncology, Sint Antonius Hospital, Department of Gynecology and Obstetrics, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial.Org: Centre Léon Bérard, Centre Paul Papin, Lorraine Cancer Institute, Hôpital Européen Georges Pompidou, CHU Hautepierre,
Abstract
Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer.Org: University of California, San Francisco, The University of California, San Francisco, University of Colorado Comprehensive Cancer Center, UC Davis Comprehensive Cancer Center, Dana-Farber Cancer Institute,
Abstract
Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.Org: Gustave Roussy Cancer Center, University of Pennsylvania, National Cancer Center Hospital East, Kashiwa, Japan, Seoul National University Bundang Hospital, Yonsei University College of Medicine,
Abstract
The ticking “biological clock”: Reproductive assistance, costs, and elective fertility preservation in female oncologists and trainees.Org: The University of Texas MD Anderson Cancer Center, UT Health San Antonio, MD Anderson Cancer Center, Baylor College of Medicine, University of Pennsylvania, Central Connecticut Radiation Oncology,
Abstract
Effect of germline mutations on somatic alteration landscapes in BRCA-associated cancers.Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Tempus Labs, Inc., University of Minnesota, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota,
Abstract
Redefining early-onset cancer and risk of hereditary cancer predisposition.Org: Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Sarcoma Medical Oncology Service,
Abstract
Germline alterations in patients with lung cancer.Org: Tempus Labs, Inc., Washington University School of Medicine, Washington University in Saint Louis,
Abstract
The clinical value of tumor-informed minimal residual disease detection in sarcoma.Org: Department of Stomatology, the Third Affiliated Hospital of Southern Medical University, Guangzhou, China, Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, Shanghai OrigiMed Co., Ltd., Shanghai, China,
Abstract
Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.Org: Department of Experimental Oncology, Milano, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Vall d'Hebron University Hospital, Bergonié Institute,
Abstract
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.Org: Melanoma Institute Australia, Mater and Royal North Shore Hospitals, Leiden University Medical Center, University Medical Center Utrecht, University Medical Center Groningen,
Abstract
Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).Org: Agendia BV, Agendia NV, Lombardi Cancer Center Georgetown University, Agendia, Agendia, Inc.,
Abstract
Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI).Org: Department of Medical, Surgical and Health Sciences, University of Trieste, Medical Oncology, Azienda Ospedaliera Universitaria Integrata di Verona, Thoracic Oncology Department & CIC Inserm 1425, Hôpital Bichat Claude Bernard, AP-HP.Nord, Foch Hospital, Centre Hospitalier Universitaire de Grenoble (France),
Abstract
KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.Org: Department of Medicine, Division of Oncology, Stanford University, Stanford Cancer Institute, Stanford, CA, Centre Hospitalier de l’Universite de Montreal, Montreal, QC, Canada, Kanagawa Cancer Center, Yokohama, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Department of Internal Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking, Beijing, China, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Pek, Beijing, China, Beijing Cancer Hospital, Beijing, China, University Hospitals Leuven, Leuven, Belgium, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, Zentralklinik Bad Berka GmbH, Bad Berka, Germany, Sanatorio Parque, Santa Fe, Argentina, HIA SAINTE ANNE, Toulon, France, Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas De Gran Canaria, Spain, Memorial Sloan Kettering Cancer Center, New York, NY, University of Turin, AOU San Luigi Orbassano, Turin, Italy, Merck & Co., Inc., Rahway, NJ, Merck and Co, Inc., Rahway, NJ, Merck & Co., Inc., Kenilworth, NJ, McGill University Health Center, Montreal, QC, Canada,
Abstract
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.Org: University College London Cancer Institute, University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Medical College of Wisconsin, Peter MacCallum Cancer Centre, Melbourne, Australia, Hematology Clinic,
Abstract
Frailty status determined by an electronic health record embedded frailty index and hospitalization risk among older adults following the initiation of cancer chemotherapy.Org: Wake Forest University School of Medicine, Levine Cancer Institute, Wake Forest Baptist Comprehensive Cancer Center,
Abstract
Cost-utility of geriatric assessment in older adults with cancer: Results from the 5C trial.Org: Lawrence S. Bloomberg Faculty of Nursing, Turpanjian College of Health Sciences, Western University, McMaster University and Juravinski Cancer Centre, Bruyere Research Institute,
Abstract
Primary overall survival analysis of the phase 3 randomized ZUMA‑7 study of axicabtagene ciloleucel versus standard‑of‑care therapy in relapsed/refractory large B-cell lymphoma.Org: Vanderbilt University Cancer Center, University of Amsterdam, Stanford University School of Medicine, Washington University School of Medicine, Hematology Department, Institut Català d'Oncologia-Hospitalet,
Abstract
Electronic frailty index predicts 30-day mortality from chemotherapy in breast, colorectal and lung cancer.Org: King's College London, Surrey Clinical Trials Unit, National Disease Registration Service, Data and Analytics; NHS England, University of Surrey, Guy's and St Thomas' NHS Foundation Trust,
Abstract
Web-based patient-reported outcome measures (PROMs) in elderly cancer patients: A French multicentric prospective feasibility trial (the FASTOCH study).Org: Ana Health, Centre Hospitalier Louis Pasteur, Dedalus, Centre Saint Jean, Vendôme Hospital,
Abstract
Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study.Org: Institut de Cancerologie de l'Ouest, ICO Institut de Cancerologie de l'Ouest, Institut de Cancérologie de l'Ouest, Centre Antoine Lacassagne, Centre Georges Francois Leclerc,
Abstract
First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.Org: PACAN platform, Unité d'Oncogériatrie, Department of Geriatrics, Institut Paoli-Calmettes, Marseille, France, Institut Curie, Saint Cloud, France,
Abstract
Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.Org: Memorial Sloan Kettering Cancer Center, Kanagawa Cancer Center, Severance Hospital, Hospital Clinic de Barcelona, Barcelona, Spain, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort.Org: Fudan University Shanghai Cancer Center, China National Biotec Group, West China Hospital, Chengdu Origen Biotechnology, Department of Preventive Medicine,
Abstract
Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS).Org: Aichi Cancer Center Hospital, Osaka University Graduate School of Medicine, Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Toranomon Hospital, St. Marianna University Hospital,
Abstract
The association of centromere amplification and response to trastuzumab in HER2+ metastatic breast cancer.Org: School of Biotechnology, Medical Oncology Department, CCRT/The Caroline Foundation, Galway University Hospital, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.Org: Harbin Medical University Cancer Hospital, Harbin, China, Department of Breast Medicine, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China, Departments of Oncology, General Hospital of Ningxia Medical University, Yinchuan, China, Department of Breast Oncology, Cancer Hospital of Xinjiang Medical University, Urumuqi, China, Breast Cancer Center, Affiliated Cancer Hospital of Chongqing University, Chongqing, China,
Abstract
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.Org: Université Libre de Bruxelles (ULB), Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium, Breast International Group, Brussels, Belgium, Dana-Farber Cancer Institute, Vall d’Hebron Institute of Oncology (VHIO),
Abstract
Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.Org: Harvard Medical School, Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Cyclin E cytoplasmatic isoform to predict outcome and benefit to capecitabine treatment in patients with HR+/HER2- metastatic breast cancer from the GEICAM/2013-02 PEARL study.Org: Instituto Valenciano de Oncología, Institut Català d'Oncologia (ICO) & IDIBELL, Medical University Vienna, Central European Cooperative Oncology Group, Medical Oncology Department,
Abstract
Early prediction of endocrine responsiveness in ER+/HER2 negative MBC: Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.Org: EO Ospedali Galliera, University Hospital Munich, International Breast Cancer Center (IBCC), Vall d'Hebron Institute of Oncology, Maggiore della Carità University Hospital,
Abstract
Prostate-specific membrane antigen (PSMA) expression in patients with metastatic triple negative breast cancer: Initial results of the PRISMA study.Org: Academic Trials Promoting Team, Nuclear Medicine Department, Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B), Medical Oncology Department,
Abstract
Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.Org: University of California Comprehensive Cancer Center, San Francisco, CA, University of California, San Francisco, San Francisco, CA, University of Texas MD Anderson Cancer Center, Houston, TX, UC Davis, Davis, CA, Masonic Cancer Center, Minneapolis, MN,
Abstract
ECOG-ACRIN E2197: Comparison of HER2 gene expression by RT-PCR across all HER2 immunohistochemistry groups with recurrence analysis.Org: Exact Sciences Corporation, Genomic Health Inc, Fred Hutchinson Cancer Research Center, Tisch Cancer Institute, Fox Chase Cancer Center,
Abstract
AI-based HER2-low IHC scoring in breast cancer across multiple sites, clones, and scanners.Org: Institute of Pathology, University of Regensburg, Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Mindpeak GmbH, Institute of Pathology, Clinical Center Osnabrueck, Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany, Nationales Centrum für Tumorerkrankungen, Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, Germany, Institute of Pathology, Philipps-University Marburg and University Hospital Marburg, Marburg, Germany, Pathologie, Universitätsklinikum Heidelberg, Heidelberg, Germany, Interdisciplinary Breast Center, Rotkreuz-Clinics Munich, Munich, Germany, Goethe-Universität Frankfurt, UCT-Frankfurt-Marburg, Frankfurt, Germany, Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin, Germany, SRH Waldklinikum Gera GmBH, Gera, Germany, Institut für Versorgungsforschung, Koblenz, Germany, Kantonsspital St.Gallen, Brustzentrum, Departement Interdisziplinäre medizinische Dienste, St. Gallen, Switzerland, Gynäkologie, Rotkreuzklinikum München, München, Germany, HELIOS Clinic Berlin-Buch, Berlin, Germany, University Hospital Frankfurt, Frankfurt Am Main, Germany, Department of Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany, German Breast Group GmbH, Neu-Isenburg, Germany, German Breast Group (GBG), Neu-Isenburg, Germany, German Breast Group, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany, Department of Obstetrics and Gynecology, University Hospital Erlangen, Erlangen, Germany,